As of 2024-12-14, the Relative Valuation of Cymabay Therapeutics Inc (CBAY) is (21.66) USD. This relative valuation is based on P/E multiples. With the latest stock price at 32.48 USD, the upside of Cymabay Therapeutics Inc based on Relative Valuation is -166.7%.
The range of the Relative Valuation is (13.60) - (21.72) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 23.7x | 22.3x |
| Forward P/E multiples | 14.8x - 25.3x | 24.9x |
| Fair Price | (13.60) - (21.72) | (21.66) |
| Upside | -141.9% - -166.9% | -166.7% |
| Date | P/E |